Our team comprises of experts in clinical neuroscience, neuroimaging, and computer science, using Artificial Intelligence algorithms and advanced imaging analytics to provide insights into the cause and progression of neurological diseases.
Through the development of more accurate and descriptive neurological imaging, new biomarkers will be used in research, clinical trials and clinical practice, to aid the diagnosis and monitoring of brain diseases.
Recent progress in magnetic resonance imaging (MRI) technology and artificial intelligence (AI) has opened new doors for both fundamental and clinical investigations in the field of clinical neuroscience.
Our team has achieved considerable success in the area of imaging biomarker research, specifically by employing advanced imaging analytics and developing state-of-the-art deep learning algorithms, with a particular focus on patients with neurodegenerative disease such as multiple sclerosis (MS).
The scope of our imaging biomarker research has expanded to encompass a variety of neurological disorders, such as Motor Neurone Disease, Epilepsy, Essential Tremor, Parkinson's disease, dementia, and Ataxia, among others. Our work spans disease diagnostics, monitoring of disease progression, and investigation into disease mechanisms. Our team extends a multitude of engaging opportunities for collaborative imaging research, industry partnerships, and bespoke research endeavours.
Seamless integration of imaging and world-class clinical care with research, education, and industry (including Pharma) is the backbone of our group. The multidisciplinary synthesis of clinical medicine, research and industry while centred with clinical care, ensures accelerated “bench-to-bedside translation” of our research activity.
Dr. Lei Bai
Dr. Heidi Beadnall
Dr. Arkiev D’Souza
Dr. Tom Close
Dr. Ryan Sullivan
Dr. Christina Maher
Dr. Marinda Taha
Dr. Linda Ly
Ms Jessie Fu
Mrs Joy Wang